{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:26:57Z","timestamp":1787167617517,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s13555-025-01495-y","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T10:03:50Z","timestamp":1752919430000},"page":"2657-2666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reduction in Facial Sebum Production Following Treatment with Clascoterone Cream 1% in Patients with Acne Vulgaris: 12-Week Interim Analysis"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06415279","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Zoe D.","family":"Draelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kizito","family":"Kyeremateng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Squittieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"issue":"4","key":"1495_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/bjd.20882","volume":"186","author":"H Chen","year":"2022","unstructured":"Chen H, Zhang TC, Yin XL, Man JY, Yang XR, Lu M. Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019. Br J Dermatol. 2022;186(4):673\u201383.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1495_CR2","doi-asserted-by":"publisher","first-page":"2296855","DOI":"10.1080\/09546634.2023.2296855","volume":"35","author":"JQ Del Rosso","year":"2024","unstructured":"Del Rosso JQ, Kircik L. The primary role of sebum in the pathophysiology of acne vulgaris and its therapeutic relevance in acne management. J Dermatolog Treat. 2024;35(1):2296855.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"1495_CR3","doi-asserted-by":"publisher","first-page":"1006.e1","DOI":"10.1016\/j.jaad.2023.12.017","volume":"90","author":"RV Reynolds","year":"2024","unstructured":"Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-e30.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1495_CR4","first-page":"412","volume":"18","author":"C Rosette","year":"2019","unstructured":"Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. Cortexolone 17alpha-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"1495_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13454","volume":"29","author":"Y Liu","year":"2023","unstructured":"Liu Y, Jiang W, Tang Y, et al. An optimal method for quantifying the facial sebum level and characterizing facial sebum features. Skin Res Technol. 2023;29(9): e13454.","journal-title":"Skin Res Technol"},{"issue":"6","key":"1495_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.36849\/JDD.7587","volume":"22","author":"H Baldwin","year":"2023","unstructured":"Baldwin H, Farberg A, Frey C, et al. Unmet needs in the management of acne vulgaris: a consensus statement. J Drugs Dermatol. 2023;22(6):582\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1495_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamadermatol.2020.0465","volume":"156","author":"A Hebert","year":"2020","unstructured":"Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621\u201330.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1495_CR8","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1111\/j.1600-0846.2011.00605.x","volume":"19","author":"BY Kim","year":"2013","unstructured":"Kim BY, Choi JW, Park KC, Youn SW. Sebum, acne, skin elasticity, and gender difference-which is the major influencing factor for facial pores? Skin Res Technol. 2013;19(1):e45-53.","journal-title":"Skin Res Technol"},{"issue":"5","key":"1495_CR9","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/j.1365-2133.2006.07465.x","volume":"155","author":"M Roh","year":"2006","unstructured":"Roh M, Han M, Kim D, Chung K. Sebum output as a factor contributing to the size of facial pores. Br J Dermatol. 2006;155(5):890\u20134.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1495_CR10","first-page":"333","volume":"13","author":"A Alexis","year":"2014","unstructured":"Alexis A, Daniels SR, Johnson N, Pompilus F, Burgess SM, Harper JC. Development of a new patient-reported outcome measure for facial acne: the Acne Symptom and Impact Scale (ASIS). J Drugs Dermatol. 2014;13(3):333\u201340.","journal-title":"J Drugs Dermatol"},{"key":"1495_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1477-7525-6-80","volume":"6","author":"R Arbuckle","year":"2008","unstructured":"Arbuckle R, Atkinson MJ, Clark M, et al. Patient experiences with oily skin: the qualitative development of content for two new patient reported outcome questionnaires. Health Qual Life Outcomes. 2008;6:80.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1495_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/13625180500252638","volume":"11","author":"HT Kranzlin","year":"2006","unstructured":"Kranzlin HT, Nap MA. The effect of a phasic oral contraceptive containing Desogestrel on seborrhea and acne. Eur J Contracept Reprod Health Care. 2006;11(1):6\u201313.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"4","key":"1495_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/13625180008500411","volume":"5","author":"HI Katz","year":"2000","unstructured":"Katz HI, Kempers S, Akin MD, Dunlap F, Whiting D, Norbart TC. Effect of a desogestrel-containing oral contraceptive on the skin. Eur J Contracept Reprod Health Care. 2000;5(4):248\u201355.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"4","key":"1495_CR14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.contraception.2008.10.010","volume":"79","author":"E Palombo-Kinne","year":"2009","unstructured":"Palombo-Kinne E, Schellschmidt I, Schumacher U, Graser T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol\/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol\/2 mg cyproterone acetate. Contraception. 2009;79(4):282\u20139.","journal-title":"Contraception"},{"issue":"11","key":"1495_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2165\/00044011-200828110-00004","volume":"28","author":"M Kerscher","year":"2008","unstructured":"Kerscher M, Reuther T, Bayrhammer J, Schramm G. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study. Clin Drug Investig. 2008;28(11):703\u201311.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1495_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/15569527.2021.1922434","volume":"40","author":"G Gencebay","year":"2021","unstructured":"Gencebay G, Askin O, Serdaroglu S. Evaluation of the changes in sebum, moisturization and elasticity in acne vulgaris patients receiving systemic isotretinoin treatment. Cutan Ocul Toxicol. 2021;40(2):140\u20134.","journal-title":"Cutan Ocul Toxicol"},{"issue":"8","key":"1495_CR17","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/ijd.15485","volume":"60","author":"SE Aksac","year":"2021","unstructured":"Aksac SE, Bilgili SG, Yavuz GO, Yavuz IH, Aksac M, Karadag AS. Evaluation of biophysical skin parameters and hair changes in patients with acne vulgaris treated with isotretinoin, and the effect of biotin use on these parameters. Int J Dermatol. 2021;60(8):980\u20135.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1495_CR18","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3906\/sag-1507-31","volume":"46","author":"E Colgecen","year":"2016","unstructured":"Colgecen E, Ozyurt K, Ferahbas KA. The effect of systemic isotretinoin treatment on skin biophysical parameters among patients with acne vulgaris. Turk J Med Sci. 2016;46(6):1641\u20134.","journal-title":"Turk J Med Sci"},{"issue":"6","key":"1495_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5114\/pdia.2013.39432","volume":"30","author":"ML Kmiec","year":"2013","unstructured":"Kmiec ML, Pajor A, Broniarczyk-Dyla G. Evaluation of biophysical skin parameters and assessment of hair growth in patients with acne treated with isotretinoin. Postepy Dermatol Alergol. 2013;30(6):343\u20139.","journal-title":"Postepy Dermatol Alergol"},{"issue":"11","key":"1495_CR20","first-page":"CD009435","volume":"11","author":"CS Costa","year":"2018","unstructured":"Costa CS, Bagatin E, Martimbianco ALC, et al. Oral isotretinoin for acne. Cochrane Database Syst Rev. 2018;11(11):CD009435.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1495_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/ics.12258","volume":"38","author":"JM Crowther","year":"2016","unstructured":"Crowther JM. Method for quantification of oils and sebum levels on skin using the Sebumeter((R)). Int J Cosmet Sci. 2016;38(2):210\u20136.","journal-title":"Int J Cosmet Sci"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01495-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01495-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01495-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:43:47Z","timestamp":1757256227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01495-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1495"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01495-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Zoe D. Draelos was an investigator on this study and received a grant from Sun Pharma. She is also an editorial board member of\n                      Dermatology and Therapy\n                      . Zoe D. Draelos was not involved in the selection of peer reviewers for the manuscript, nor in any of the subsequent editorial decisions. Kizito Kyeremateng and Nicholas Squittieri are employees of Sun Pharmaceutical Industries, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with Good Clinical Practice guidelines and all local legal and regulatory requirements and was registered with ClinicalTrials.gov (NCT06415279). Institutional review board (Allendale Institutional Review Board, Old Lyme, CT) approval was obtained for the study protocol. All patients (and\/or a legally acceptable representative, as applicable) were required to provide written informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}